Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.
Press releases published on June 2, 2025
Miata Metals Signs Option to Increase Ownership of the Nassau Gold Project in Suriname to 100%
GlobeNewswire
·
June 2, 2025
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Vancouver, BC (June 2, 2025) – Miata Metals Corp. (CSE: MMET) (FSE: 8NQ) (OTCQB:MMETF) (“Miata” or the “Company”) is pleased to announce that it has entered into an option agreement (the “ …
New Wave Appoints New Chief Executive Officer
GlobeNewswire
·
June 2, 2025
Vancouver, BC, June 02, 2025 (GLOBE NEWSWIRE) -- New Wave Holdings Corp. (“New Wave” or the “Company”) (CSE:NWAI, FWB:0XM0, OTCPK:TRMNF) announces that Mr. Joshua Matettore has been appointed as Chief Executive Officer (“CEO”) of the Company effective …
[Latest] Global Hybrid Powertrain Market Size/Share Worth USD 483.33 Billion by 2034 at a 15.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value, SWOT Analysis)
GlobeNewswire
·
June 2, 2025
Austin, TX, USA, June 02, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hybrid Powertrain Market Size, Trends and Insights By Type (Full Hybrid (HEV), Mild Hybrid (MHEV), Plug-In Hybrid (PHEV)), By Vehicle Type …
Sanborn Achieves SOC 2 Type 2 Attestation, Reinforcing Commitment to Data Security and Operational Integrity
GlobeNewswire
·
June 2, 2025
COLORADO SPRINGS, Colo., June 02, 2025 (GLOBE NEWSWIRE) -- The Sanborn Map Company, Inc. (Sanborn), a leader in geospatial solutions and data services, is proud to announce that it has successfully completed a SOC 2 Type 2 audit. This independent …
Green electricity + cloud mining new trend: RichMiner's three secrets to create low-carbon passive income
GlobeNewswire
·
June 2, 2025
New York, NY, June 02, 2025 (GLOBE NEWSWIRE) -- The annual electricity consumption of global cryptocurrency mining has exceeded Argentina's national electricity consumption (data from Cambridge University). Today, when carbon emission reduction has become …
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
GlobeNewswire
·
June 2, 2025
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar profile to the only FDA-approved GLP-1/GIP receptor …
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
GlobeNewswire
·
June 2, 2025
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: …
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
GlobeNewswire
·
June 2, 2025
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be …
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
GlobeNewswire
·
June 2, 2025
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next- …
Sanofi Exercises License Extension Option to Nurix’s STAT6 Program
GlobeNewswire
·
June 2, 2025
STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the …
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
June 2, 2025
(OXFORDSHIRE, England …
Plum Wins Gold at the 5th Annual 2025 Globee® Awards for Disruptors
GlobeNewswire
·
June 2, 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Revolutionary pre-hire assessment provider Plum is proud to announce that it has been named a winner of the Gold Technology Industry Disruptor at the 5th Annual 2025 Globee® Awards for Disruptors, a prestigious …
ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare workforce shortage
GlobeNewswire
·
June 2, 2025
LOS ANGELES, June 02, 2025 (GLOBE NEWSWIRE) -- InStride, a leading provider of strategic education and skilling solutions, has facilitated a unique partnership between Arizona State University’s College of Health Solutions and Labcorp, a global leader of …
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
GlobeNewswire
·
June 2, 2025
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., …
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
GlobeNewswire
·
June 2, 2025
--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in …
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
GlobeNewswire
·
June 2, 2025
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically significant improvement …
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire
·
June 2, 2025
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as …
Denodo University Challenge Now Open: Data and AI for Real-World Impact
GlobeNewswire
·
June 2, 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Denodo, a leader in data management, announced that the Denodo Academic Program, which prepares students to become future leaders in the field of data and analytics, has opened registration for the next …
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
GlobeNewswire
·
June 2, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical …
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
GlobeNewswire
·
June 2, 2025
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all …